These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 1469397)

  • 21. Apomorphine for motor fluctuations and freezing in Parkinson's disease.
    Corboy DL; Wagner ML; Sage JI
    Ann Pharmacother; 1995 Mar; 29(3):282-8. PubMed ID: 7606075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment possibilities in advanced Parkinson's disease].
    Takáts A; Nagy H; Radics P; Tóth A; Tamás G
    Ideggyogy Sz; 2013 Nov; 66(11-12):365-71. PubMed ID: 24555235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A; Turner K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The motor response to repeated apomorphine administration in Parkinson's disease.
    Hughes AJ; Bishop S; Stern GM; Lees AJ
    Clin Neuropharmacol; 1991 Jun; 14(3):209-13. PubMed ID: 2070362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Pharmacother; 2020 Oct; 21(14):1659-1665. PubMed ID: 32640853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subcutaneous apomorphine in the treatment of Parkinson's disease.
    Frankel JP; Lees AJ; Kempster PA; Stern GM
    J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):96-101. PubMed ID: 2313313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apomorphine infusion and the long-duration response to levodopa in advanced Parkinson's disease.
    Stocchi F; Berardelli A; Vacca L; Barbato L; Monge A; Nordera G; Ruggieri S
    Clin Neuropharmacol; 2003; 26(3):151-5. PubMed ID: 12782918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
    Mouradian MM; Heuser IJ; Baronti F; Giuffra M; Conant K; Davis TL; Chase TN
    J Neurol Neurosurg Psychiatry; 1991 May; 54(5):401-5. PubMed ID: 1865201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levodopa consumption reduces dopaminergic receptor responsiveness in Parkinson's disease.
    Vaamonde J; Luquin MR; Obeso JA
    Clin Neuropharmacol; 1989 Aug; 12(4):271-84. PubMed ID: 2804991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of acute levodopa withdrawal on motor performance and dopaminergic receptor sensitivity in patients with Parkinson's disease.
    Turjanski N; Fernandez W; Lees AJ
    J Neurol Neurosurg Psychiatry; 1993 Jul; 56(7):771-5. PubMed ID: 8331352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of Parkinson's disease with aporphines. Possible role of growth hormone.
    Cotzias GC; Papavasiliou PS; Tolosa ES; Mendez JS; Bell-Midura M
    N Engl J Med; 1976 Mar; 294(11):567-72. PubMed ID: 1107835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Sublingual administration of apomorphine in the treatment of motor fluctuations in Parkinson disease].
    Durif F; Deffond D; Eschalier A; Tournilhac M
    Rev Neurol (Paris); 1992; 148(10):610-4. PubMed ID: 1295055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment.
    Ray-Chaudhuri K; Abbott RJ; Millac PA
    J Neurol Neurosurg Psychiatry; 1991 Apr; 54(4):372-3. PubMed ID: 2056329
    [No Abstract]   [Full Text] [Related]  

  • 35. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
    Kanovský P; Kubová D; Bareš M; Hortová H; Streitová H; Rektor I; Znojil V
    Mov Disord; 2002 Jan; 17(1):188-91. PubMed ID: 11835461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
    Hughes AJ; Bishop S; Kleedorfer B; Turjanski N; Fernandez W; Lees AJ; Stern GM
    Mov Disord; 1993 Apr; 8(2):165-70. PubMed ID: 8474483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study.
    Merello M; Pikielny R; Cammarota A; Leiguarda R
    Clin Neuropharmacol; 1997 Apr; 20(2):165-7. PubMed ID: 9099469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The motor response to sequential apomorphine in parkinsonian fluctuations.
    Hughes AJ; Lees AJ; Stern GM
    J Neurol Neurosurg Psychiatry; 1991 Apr; 54(4):358-60. PubMed ID: 2056323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Motor response to apomorphine and levodopa in asymmetric Parkinson's disease.
    Rodriguez M; Lera G; Vaamonde J; Luquin MR; Obeso JA
    J Neurol Neurosurg Psychiatry; 1994 May; 57(5):562-6. PubMed ID: 8201324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.